APELOA proudly introduces our latest API product, Gabapentin! Developed using an innovative process that eliminates a reaction step compared to traditional process, we have achieved a more sustainable production method with reduced environmental impact. This not only supports global carbon reduction efforts but also enhances cost efficiency.
Gabapentin is manufactured in our newly designed, state-of-the-art facility, equipped with scalable production capabilities and adhering to world-class quality standards. With multiple US FDA approvals, rigorous audits from other leading authorities, and a dedicated regulatory team, we are committed to delivering high-quality, compliant products that meet global benchmarks.
Gabapentin represents a significant milestone in our mission to responsibly advance healthcare worldwide.
